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  1 
SUMMARY 
Objective:  
Androgen deprivation therapy is the treatment of choice in advanced prostate cancer, yet 
patients generally relapse and progress to an androgen independent state within 18-24 
months. The PI3K/Akt pathway is known to represent one of a number of routes to 
hormone resistance and this study assessed the role of selected downstream Bcl-2 family 
members (Bad, Bax, Bcl-2 and Bcl-xL) in the development of androgen independent 
prostate cancer (AIPC). 
Materials and Methods:  
Immunohistochemistry was performed on matched hormone sensitive and hormone 
refractory tumours. Staining was scored by 2 independent observers using a weighted 
histoscore method. Change in Bad, Bax and Bcl-xL expression during transition to AIPC 
was evaluated and then correlated to known clinical parameters.   
Results:  
High Bad expression in androgen sensitive tumours was associated with increased time to 
biochemical relapse (p=0.0072) and a trend towards improved overall survival 
(p=0.0532) was observed.  There were also trends towards a fall in Bad (p=0.068) and 
Bax (0.055) expression with progression to AIPC.  No significant results were yielded for 
Bcl-2 or Bcl-xL.   
Conclusion:  
There is evidence to suggest that Bad expression levels at diagnosis influence time to 
biochemical relapse and overall survival, and that levels of pro-apoptotic proteins Bad 
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and Bax fall during AIPC development.  Bad may therefore represent a possible positive 
prognostic marker and potential therapeutic target for AIPC in the future.    
 
  3 
INTRODUCTION 
 
Prostate cancer is the most common malignancy among men in the UK and remains the 
second-leading cause of male cancer-specific mortality after lung cancer, being 
responsible for nearly 10,000 deaths in the UK each year [1].  Androgen deprivation 
therapy (ADT) has remained the treatment of choice in advanced prostate cancer since 
the observations made by Huggins and Hodges in the 1940s [2].  While initial response 
rates to ADT are high, patients generally relapse within 18-24 months [3] with rising PSA 
levels indicative of progression to hormone refractory or androgen independent prostate 
cancer (AIPC) [3].  There are few therapeutic options available to patients after transition 
to the androgen independent state; second-line ADT, chemotherapy and radiotherapy can 
be beneficial in symptom control, however approach to management is generally of a 
palliative intent [4] and the median survival of patients after progression to androgen 
independence is just 12 months [3].  It is therefore important that we further our 
knowledge of the molecular mechanisms driving the development of AIPC, in doing so 
new therapeutic targets may be identified, leading to the development of effective 
treatments for this patient group. 
 
There is evidence to suggest that receptor tyrosine kinases (RTKs), such as EGFR and 
HER2, in the plasma membrane contribute to hormone escape in prostate cancer [5, 6]. 
The PI3K/Akt pathway is activated via RTKs in response to extracellular growth and 
survival factors and represents one of a number of independent routes to androgen escape 
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in prostate cancer [7].  Having previously observed activation of the cascade in this 
laboratory [7], it was appropriate to examine the activity of downstream members.   
 
Akt is a protein capable of influencing cellular proliferation and survival in several ways, 
including inhibition of apoptosis via phosphorylation of the pro-apoptotic protein Bad 
[8].  Bad is a member of the Bcl-2 family, a group comprising proteins which are 
important regulators of apoptosis.  The proteins are divided into three groups according to 
their relative actions and the number of Bcl-homology (BH) domains present [8].  The 
pro-survival family members include Bcl-2 and Bcl-xL, and are located in the outer 
mitochondrial membrane where they have the capacity to inhibit specific apoptotic 
stimuli [8, 9].  There are two groups of pro-apoptotic proteins; Bax/Bak-like proteins and 
BH3-only proteins.  Bax and Bak have the ability to disrupt the outer mitochondrial 
membrane, resulting in the release of apoptogenic molecules, such as cytochrome c, from 
the mitochondria into the cytoplasm, leading to cell death [8]. Bad, Bim and Bid act 
upstream of Bax and Bak and are examples of BH3-only proteins which exert their pro-
apoptotic influence by binding to and antagonizing pro-survival members and/or by 
activating the pro-apoptotic Bax/Bak-like members [8]. 
 
The BH3-only protein Bad acts principally by heterodimerizing with either of pro-
survival proteins Bcl-xL and Bcl-2, however it appears to bind more strongly to Bcl-xL 
in mammalian cells [9]. Bad associates with Bcl-xL or Bcl-2 and modulates its survival 
functions by preventing Bcl-xL or Bcl-2 from binding to and thereby hindering the death-
promoting actions of Bax and Bak [10].  Therefore when Bad binds to Bcl-xL or Bcl-2, 
  5 
Bax and Bak can continue to exert their pro-apoptotic influence, causing the release of 
apoptogenic molecules from the mitochondria into the cytosol, which culminates in 
caspase activation and cell death [10].   Bad undergoes translocation from the cytosol to 
the outer mitochondrial membrane during the apoptotic process [11]. 
 
Bad comprises 23 serines and 10 threonines within 204 amino acids, and of these, serines 
112, 136 and 155 have been identified as key phosphorylation sites [12]. Phosphorylation 
by Akt at Ser136 prevents the association of Bad with Bcl-xL or Bcl-2 on the outer 
membrane of mitochondria, and causes alteration in Bad sub-cellular distribution from 
mitochondria to bind to 14-3-3 proteins present in the cytosol [12, 13].  Bad is 
sequestered in the cytoplasm by 14-3-3 proteins and therefore unable to perform pro-
apoptotic activities [12, 13].  As a result, Bcl-xL and Bcl-2 are free to support cell 
survival and thus bind to and antagonize the actions of Bax and Bak.   
 
Analysis of these events at a molecular level has not been a straightforward task, since 
most prostate tumours available for study only represent the disease at time of diagnosis, 
as it is not usual practice to take biopsies of recurrent disease [14].  However, this study 
measures the expression of selected Bcl-2 family members, namely Bad, Bax, Bcl-xL and 
Bcl-2, in paired androgen dependent and androgen independent tumour specimens, in 
order to further characterise the role of this protein family in the development of AIPC. 
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MATERIALS AND METHODS 
 
Patient cohort 
 
The patient cohort was established by retrospectively selecting prostate cancer patients 
who demonstrated an initial response to ADT, but subsequently relapsed with AIPC.  
This provided the following numbers of matched androgen dependent and androgen 
independent tumour pairs for analysis; 58 (Bad and Bcl-xL), 53 (Bax) and 51 (Bcl-2), it 
was originally planned to do 58 pairs for all proteins, however some pairs were lost due 
to insufficient tissue.  Tumours classed as androgen dependent were obtained from 
patients diagnosed with locally advanced or metastatic prostate cancer who had received 
surgery, followed by conventional ADT.  Inclusion criteria were applied according to 
Djavan et al. 2003 [15]. In order to meet the inclusion criteria a response to ADT had to 
be observed; defined as a fall in PSA levels by at least 50%, with a nadir being reached of 
less than 0.1 ng/ml. The androgen dependent samples were obtained from either a TURP 
or a TRUS-guided biopsy.  Patients were also required to relapse with AIPC to meet the 
inclusion criteria; relapse corresponded to failure of ADT and was defined clinically as 2 
consecutive rises in PSA concentration greater than 10%, PSA levels had to rise to more 
than 0.4ng/ml to have clinically relevance and disease recurrence had to be within 6-49 
months following surgery.  Following identification of these patients, androgen 
independent tumour specimens were only available for analysis if additional surgery was 
required to treat the clinical symptoms of bladder outflow obstruction, and therefore 
androgen independent tumour samples were obtained only by TURP.  In order to further 
confirm progression to hormone refractory disease proliferation index using MIB-1 Ki67 
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staining was calculated in the cohort, proliferation index significantly increased from 2.9 
(1.2-6.1-) to 7.8 (2.7-15.8), p= 0.0001.  Androgen receptor and PSA expression was 
observed in all hormone refractory tumours. 
 
All tumours had patient identification removed, including block number and hospital 
number, and were coded to make the database anonymous.  Ethics approval was obtained 
from the Multicentre Research Ethics Committee (MREC) for Scotland and relevant 
Local Research and Ethical Committees (LREC).   
Immunohistochemistry 
 
The specificity of antibodies used in this study was confirmed by western blotting.  All 
immunohistochemistry (IHC) was performed on 5 µm, archival formalin fixed, paraffin 
embedded prostate tumour sections therefore overcoming the problem of heterogeneity.   
The sections were dewaxed in xylene and then rehydrated through graded alcohols.  
Antigen retrieval was performed by incubating sections in antigen unmasking solution at 
96ºC for 25 minutes (Bad) or 40 minutes (Bax), or using heat treatment under pressure in 
a Tris EDTA Buffer (Bcl-xL and Bcl-2). Endogenous peptidase was destroyed by 
incubating sections in H2O2 at the following concentrations; 0.3% for 20 minutes (Bad), 
1% for 10 minutes (Bax and Bcl-2), 3% for 10 minutes (Bcl-xL).  Non-specific 
background staining was blocked using horse serum in TBS for 20 minutes.  The 
following antibodies and dilutions were selected; Bad (CST#9292) at 1:25, Bcl-2 (Dako 
M0887) at 1:50, Bax (Dako A3533) and Bcl-xL (CST #2762) both at 1:1000.  The 
sections were incubated with primary antibody overnight at 4ºC, except those stained for 
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Bcl-2 which were incubated for 1 hour at room temperature.  Staining was developed 
using the EnVision kit (DakoCytomation, Glostrup, Denmark), and chromagen was 
detected using DAB (Vector Labs, UK).  A positive and negative control slide was 
included in each IHC run.  Slides were counterstained in haematoxylin and Scotts tap 
water substitute, dehydrated through graded alcohols and xylene, and lastly mounted in 
DPX. 
 
Scoring 
 
Tissue staining intensity was scored blind by 2 independent observers using a weighted 
histoscore method.   Histoscores were calculated from the sum of (1 x % cells staining 
weakly positive) + (2 x % cells staining moderately positive) + (3 x % cells staining 
strongly positive), with a maximum of 300.  Inter-class correlation coefficients (ICCC) 
were calculated to confirm consistency between observers and ICCC >0.7 was 
acceptable. The mean of the two observers scores was used for analysis 
 
Statistics 
 
All statistical analyses were performed using SPSS version 11 for windows.  Wilcoxon 
signed rank tests were used to compare expression between androgen dependent and 
androgen independent tumours.  Survival analysis was conducted using the Kaplan Meier 
method and curves were compared using the log rank test.  Multivariate analysis and 
hazard ratios were performed using Cox Regression analysis.  A value of p<0.05 was 
considered statistically significant.   
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RESULTS 
 
Patient characteristics 
 
A total of 58 prostate cancer patients (diagnosed between 1984 and 2002) were included 
in this study with matched hormone sensitive and hormone refractory prostate tumours 
available for analysis (116 tumours in total).  Patients in this cohort were diagnosed with 
locally advanced (48) or metastatic prostate cancer (10) and subsequently received 
surgery and ADT (18 orchidectomy, 36 GnRH analogues, 3 had both and 1 received anti-
androgen therapy alone).  In total 38 of the 58 patients received anti-androgen therapy.  
Forty-eight patients died during the course of follow-up, and 10 patients were alive at last 
follow-up.  Thirty-three deaths (57%) were cancer-specific.  Table 1 summarises the 
main patient characteristics.   
 
Protein expression 
 
Protein expression was observed within the cytoplasm as expected. The interclass 
correlation coefficient (ICCC) for each protein was greater than 0.7 and therefore classed 
as excellent.  The median histoscores with inter-quartile range (IQR) for each protein in 
both androgen dependent and androgen independent tissue are given in table 2.  While 
Bcl-xL and Bcl-2 demonstrated no significant change in median histoscore with 
transition to androgen independence, there was a trend towards a fall in expression of 
Bad (100 to 75 units, p=0.068) (figure 1) and Bax (70 to 55 units, p=0.055). 
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Protein expression and clinical outcome 
 
When patients were divided into those with high or low levels of Bad expression (above 
or below the median histoscore), a high level of Bad expression at diagnosis (androgen 
dependent tissue) was associated with increased time to biochemical relapse (p=0.0072) 
(figure 2a).  The median time to biochemical relapse for patients whose tumours 
demonstrated low levels of Bad expression was 2.17 (1.83-2.51) years, compared to 3.26 
(0.90-5.62) years for patients whose tumours expressed high levels.  On multi variant 
analysis when combined with Gleason grade at diagnosis, Bad expression was 
independently significant for time to relapse (p=0.0325 and hazard ratio 0.50 (0.26-
0.94)).  There was a trend towards improved overall survival associated with high Bad 
expression in hormone sensitive tissue (p=0.0539); the median survival of patients whose 
tumours showed a high degree of Bad expression was 6.57 (3.61-9.53) years, in 
comparison to 4.15 (2.18-6.12) years in patients with low levels of expression (figure 2b).   
The influence of Bad expression in androgen dependent tumours upon time to relapse and 
overall survival appears to be a delayed effect.  This was confirmed following repeated 
analysis using patients relapsing or surviving beyond 24 months only, with p-values of 
0.0001 and 0.0309 obtained for time to relapse and overall survival respectively.   
 
The degree of Bad expression in androgen independent tumours was not related to either 
time to death from relapse or overall survival (p=0.6946 and 0.6376 respectively).  A 
change in protein expression with progression to hormone refractory disease was defined 
as the mean difference between the independent observers scores + 2 standard deviations 
and on this basis, change in Bad expression was determined to be 57 histoscore units.  
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However, change in Bad expression was not associated with time to biochemical relapse 
(p=0.431), time to death from biochemical relapse (p=0.359) or overall survival 
(p=0.361).   There were no significant associations between expression of Bax, Bcl-2 and 
Bcl-xL and time to relapse, time to death from relapse or overall survival (data not 
given).   
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DISCUSSION 
 
 
The association between Bad expression in androgen dependent disease and time to 
biochemical relapse was the most noteworthy finding in this study, with patients 
expressing high levels of Bad at diagnosis relapsing after a time period significantly 
longer than patients with low Bad expression (p=0.0072).  Furthermore, there is evidence 
that Bad expression at diagnosis is an independent determinant of time to relapse, as 
demonstrated by multi-variant analysis (p=0.0325).  A trend towards improved overall 
survival was observed in patients with high Bad at diagnosis (p=0.0537), the lack of 
statistical significance in this instance may be partially explained by a lack of power 
owing to the size of this patient cohort.  Power calculations estimate that approximately 
104 patients would be required to achieve a significant result in this instance.  The patient 
cohort continues to be expanded and new samples can be stained for BAD in attempt to 
strengthen existing results. 
 
Although not statistically significant, high Bad expression in androgen sensitive disease 
did confer a greater than median 2 year extended survival relative to low Bad expression.  
As the degree of Bad expression at diagnosis appears to influence clinical outcome, this 
protein may represent a possible positive prognostic indicator in this malignancy.  The 
results confirm that Bad serves a protective role in hormone sensitive disease, which 
follows as Bad is a pro-apoptotic protein capable of binding to and inhibiting anti-
apoptotic Bcl-2 family members Bcl-xL and Bcl-2, thus enabling the release of 
cytochrome c from the mitochondria and subsequent activation of the apoptosis cascade 
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[8-13].  High levels of Bad may increase apoptosis and slow down tumour growth in 
hormone sensitive prostate tumours, thereby delaying time to biochemical relapse and 
death.   Interestingly, these findings are akin to those found in a similar study of breast 
cancer tissue where patients with high Bad expression had a significantly improved 
disease-free survival compared to patients expressing low levels of Bad (p=0.049) [16].    
 
The data here suggests that influence of Bad expression at diagnosis upon both time to 
relapse and overall survival is a delayed effect occurring after an approximate 24-month 
period.  This observation may be explained by the effect of ADT therapy, which achieves 
response for up to 24 months as measured by falling PSA level.  After this time the 
protective role of BAD may become more apparent as its effects are no longer masked by 
those of ADT subsequent to hormone escape.  This observations is in agreement with that 
made in breast cancer, Cannings et al. observed that their correlation with over-
expression of Bad and disease free survival was most significant after 3 years of 
tamoxifen treatment [16].  They suggested that this is of current interest as it might 
influence decisions about switching from Tamoxifen to aromatase inhibitors.  This might 
also reflect the biological effect that androgen deprivation has on prostate cancer cells, it 
has been demonstrated that long term treatment with ADT alters expression of members 
of apoptotic pathways [17]. 
Molecular markers have the potential not only to act as prognostic markers, but to 
contribute to new therapeutic strategies thereby providing possible targets for molecular 
based intervention.  BH3 mimetics are a new class of anti-cancer drugs, and one approach 
involves the use of compounds designed to mimic pro-apoptotic proteins and shaped to 
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fit into the groove of pro-survival proteins [18].  ABT-737 is a recently described BH3 
mimetic which behaves like Bad and targets pro-survival Bcl-2, Bcl-xL and Bcl-w with 
high affinity, thus hindering their anti-apoptotic activity [19].  In prostate cancer 
specifically, adenoviral technology has been utilised to induce overexpression of Bad and 
Bax [20].  Given their pro-apoptotic role, levels of protective proteins Bad and Bax may 
be expected fall with disease progression, as demonstrated here, which reinforces the 
logic in replenishing diminished levels of these proteins in prostate cancer.    
 
That Bcl-2 was not upregulated with progression to androgen independence was an 
unexpected finding, given the body of evidence supporting an increased expression in 
AIPC [21-24].  This has most likely resulted from a difference in sample size, with some 
previous studies utilising a larger number of tissue sections, for example Zellweger et al 
[24], stained 181 localised prostate cancer and 120 hormone refractory sections noting 
significant overexpression in the latter group.   Some studies highlight Bcl-xL as the 
optimum target in prostate cancer cells [25] and it has remained uncertain as to the extent 
each of the anti-apoptotic proteins Bcl-xL and Bcl-2 serve functional roles in this disease, 
and with no significant results for either protein, this study was unable to clarify this 
matter.   Both pro-survival proteins are located in the outer mitochondria, where they can 
hinder specific apoptotic stimuli, unless bound by Bad which heterodimerizes with either 
of Bcl-xL and Bcl-2 [8, 9] and it is likely that the proteins act synergistically.  There has 
been recent interest in use of anti-sense oligonucleotides to block the action of Bcl-2 or 
Bcl-xL [26-28].  
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Bad is phosphorylated by other proteins in addition to Akt, and it would therefore be of 
interest to investigate 90-kDa serine/threonine ribosomal S6 kinase (p90RSK or MAPK-
activated protein kinase 1) for example, which is a downstream effector in the MAPK 
signalling cascade which maintains Bad in an inactive state by phosphorylation at 
Ser112, thus promoting cell survival [29, 30].  Additionally, recent cell line work 
identified the Pac/PAK1 cascade as a parallel anti-apoptotic signalling pathway, 
mediating Bad phosphorylation at Ser136 [31].   
 
Apoptotic and proliferative index studies are underway in the laboratory and it would be 
useful to assess whether expression of the Bcl-2 family members examined here 
correlates with the degree of apoptosis or proliferation occurring within the tumour 
samples.   
 
In summary, there is evidence to indicate a role for Bad in hormone sensitive prostate 
cancer, with the degree of Bad expression at diagnosis influencing time to biochemical 
relapse.  There was a trend towards improved overall survival in patients with high Bad 
expression at diagnosis. In addition, trends towards a fall in Bad and Bax expression with 
disease progression were noted.  It thus follows that Bad may represent a possible 
positive prognostic marker and useful therapeutic target in AIPC management in the 
future.   
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Figure Legends 
 
Figure 1 
Figures 1a and 1b visually demonstrate the trend to fall in Bad expression when androgen 
sensitive (1a) progresses to androgen insensitive disease (1b) observed in this study 
(p=0.068).  Magnification x400. 
 
 
 
Figure 2 
 
Kaplan-Meier plots demonstrating increased time to biochemical relapse (2a) and trend 
towards improved overall survival (2b) in patients with high levels of Bad expression at 
diagnosis (androgen dependent tumour), compared to patients with low levels of 
expression (p=0.0539). 
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Table 1 
Patient characteristics:  age (years), Gleason score (complete range 4-10), PSA level 
(ng/ml), time to biochemical relapse, time to death from relapse and overall survival are 
shown as median and interquartile range.  Metastasis is the number and percentage of 
patients with metastasis at diagnosis and relapse.  Those with metastasis at diagnosis are 
included in the number of patients with metastasis at relapse.  Note that as Gleason score 
is directly affected by ADT, the score at relapse may not necessarily reflect tumour 
biology.   
 
Age (years) at diagnosis 70.5 (66-74.25) 
Gleason score at diagnosis 8 (7-9) 
Gleason score at relapse 9 (8-9) 
PSA level at diagnosis (ng/ml) 46.50 (22.43-129.25) 
PSA level at relapse (ng/ml) 16.30 (6.33-39.60) 
Time to biochemical relapse (years) 2.32 (1.47-4.67) 
Time to death from relapse (years) 1.39 (0.75-2.46) 
Overall survival (years) 4.39 (2.81-7.04) 
Metastasis at diagnosis 10 (17.24%) 
Metastasis at relapse 30 (51.72%) 
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Table 2  
The median histoscore and inter-quartile range (IQR) for Bad and Bcl-xL expression in 
both androgen dependent and androgen independent tumour samples are shown.  P-
values derived from Wilcoxon signed rank tests are given and trends observed are 
marked with an asterisk*. 
 
 Androgen Dependent Androgen Independent P-value 
Bad 100 (61.88-130.63) 75 (36.88-120) 0.068* 
Bcl-xL 95 (68.75-155) 105 (62.50-125) 0.705 
Bax 70 (23.75-140) 55 (27.50-92.5) 0.055* 
Bcl-2 120 (60-190) 125 (50-180) 0.842 
 
 
 
 
 
 
 
 
 
 
 
 
 
